Boston Scientific Receives FDA Approval For Promus Premier Everolimus-Eluting Platinum Chromium Coronary Stent System

Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation

has received U.S. Food and Drug Administration (FDA) approval for the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's next-generation durable polymer drug-eluting stent (DES).  The technology is available immediately in the U.S., with the first implantation scheduled to be performed by Martin Leon, M.D., director, Center for Interventional Vascular Therapy at Columbia University Medical Center / New York-Presbyterian Hospital, New York City.  "It's very rewarding, professionally, to be the first to provide this new DES therapy to my patients," said Leon.  "Perhaps the most impressive benefit of the Promus PREMIER Stent System is its unparalleled visibility, which combined with enhanced customized stent architecture, leads to an advance in currently available durable polymer DES." The Promus PREMIER Stent System offers physicians improved DES performance in treating patients with coronary artery disease, and features unique customized platinum chromium alloy stent architecture, the market-leading Everolimus drug with a biocompatible, fluorinated co-polymer and an enhanced stent delivery system.  Images of the Promus PREMIER Stent System are available for download here. "After using this